EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMER'S DISEASE RESEARCH AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022
TOKYO, July 25, 2022 /PRNewswire/ — Eisai Co. Ltd (Headquarters: Toyoko, CEO: Haruo Naito, “Eisai”) announced today that…